NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis

December 4, 2018
Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis

UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharmaโ€™s …

Pfizer’s biosimilar proves non-inferior to rituximab in lymphoma at ASH 2018

December 4, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASH 2018, Pfizer, haemophilia

Joining the chorus of data presentations at the American Society of Hematology (ASH) Annual Meeting 2018, Pfizer has announced new …

shutterstock_243110086

Hemlibra shows “clinically meaningful” bleed control in paediatric haemophilia A patients

December 4, 2018
Manufacturing and Production, Research and Development ASH 2018, Hemlibra, Roche, haemophilia, pharma

In another reveal at the American Society of Hematology (ASH) Annual Meeting 2018, Roche unveiled new Phase 3 findings for …

institute_of_cancer_research

Cancer drug access for NHS patients is slowing, ICR reports

December 4, 2018
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, ICR, Institute of Cancer Research, NHS, NICE, UK, pharma

A new report from the Institute of Cancer Research (ICR) has indicated that NHS patients in the UK are suffering …

roche

Roche chooses Veeva Vault PromoMats for digital asset management and content

December 4, 2018
Manufacturing and Production, Medical Communications Roche, pharma, veeva

Today, at the 2018 Veeva Commercial & Medical Summit Europe, Roche (SWX:ROG) announced that it would be adopting Veeva Systems …

shire_image

Shire’s Takhzyro scores EU approval in rare genetic disorder hereditary angioedema

December 3, 2018
Sales and Marketing EU, Europe, Shire, Takhzyro, pharma

Shire has announced that it has secured European approval for its subcutaneous injection Takhzyro (lanadelumab) for the routine prevention of …

gilead-sciences

Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma

December 3, 2018
Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma

Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …

GSK to acquire oncology biotech Tesaro for $5.1 billion

December 3, 2018
Sales and Marketing GSK, GlaxoSmtihKline, Tesaro, acquisition, oncology, pharma

GlaxoSmithKline is set to acquire US-based oncology biotech Tesaro after both companies signed a definitive agreement with an aggregate cash …

abbvie_0

AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia

December 3, 2018
Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma

AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …

Novartis unveils strong longer-term Kymriah data at ASH 2018

December 3, 2018
Research and Development, Sales and Marketing ASH 2018, Cancer, Kymriah, Novartis, leukaemia, pharma

Novartis has lifted the curtain on longer-term analysis data for its CAR-T therapy Kymriah (tisagenlecleucel) at the American Society of …

opdivo_1_1

Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund

November 30, 2018
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma

Bristol-Myers Squibbโ€™s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …

merckwindow_web

MSD chalks up two HIV drug approvals in Europe

November 30, 2018
Medical Communications, Sales and Marketing Delstrigo, EU, Europe, HIV, MSD, Pifeltro, pharma

MSD has announced the European approval of two of its products for the treatment of HIV: the single-tablet combination Delstrigo …

brexit_flag

83% in healthcare say UK will not be attractive for R&D and manufacturing post-Brexit

November 30, 2018
Medical Communications, Research and Development R&D, UK, brexit, pharma

As the Brexit crisis continues to spiral, new findings from GlobalData reveal that 83% of healthcare professionals in the UK …

Bayer announces major restructure, 12,000 jobs to go

November 30, 2018
Medical Communications, Sales and Marketing Bayer, job cuts, monsanto, pharma

Bayer has announced a major restructure of its operations in 2019 which will see the loss of 12,000 of its …

UK is among the first to meet UN targets for HIV treatment and prevention, Public Health England says

November 29, 2018
Medical Communications HIV, UK, pharma

The UK is among the first countries in the world to meet the HIV treatment targets set out by the …

Astellas’ Xospata becomes US-approved drug for FLT3-mutated acute myeloid leukaemia

November 29, 2018
Sales and Marketing Astellas, FDA, US, Xospata, acute myeloid leukamia

Astellas has revealed that Xospata (gilteritinib) has been awarded FDA approval as a treatment for relapsed or refractory acute myeloid …

FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion

November 29, 2018
Sales and Marketing FDA, Genentech, Rituxan, Roche, Teva, Truxima, biosimilars, celltrion

The FDA has announced the first US approval of a biosimilar version of Genentechโ€™s Rituxan (rituximab), awarding marketing approval to …

Novartis’ Gilenya scores paediatric EU approval for advanced relapsing-remitting MS

November 29, 2018
Sales and Marketing Europe, Novartis, UK, multiple sclerosis, pharma

Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms …

The Gateway to Local Adoption Series

Latest content